In 28 790 patients recruited for the ONTARGET (Ongoing Treatment Alone and in
Combination With Ramipril Global End Point Trials) and TRANSCEND (Telmisartan …

Aims: There is conflicting evidence on whether in treated hypertensive patients the risk of
renal outcomes is associated with visit-to-visit SBP variability. Furthermore, limited evidence …

Visit-to-visit variability of blood pressure (VVV of BP) is gaining interest as a prognostic
marker for stroke, cardiovascular disease, and all-cause mortality. In this review, we discuss …

Recent evidence indicates that long-term visit-to-visit blood pressure variability (BPV) may
be an independent cardiovascular risk predictor. The implication of this variability in …

Objective: To assess how visit-to-visit variability of SBP correlates with systemic
atherosclerotic change and various prognoses. Background: Visit-to-visit SBP variability …

Objective: In addition to high blood pressure variability (BPV), low BPV was associated with
adverse cardiovascular prognosis in selected high-risk patients. We explored this issue in …

Studies of visit-to-visit office blood pressure (BP) variability (OBPV) as a predictor of
cardiovascular events and death in high-risk patients treated to lower BP targets are lacking …

This post hoc analysis of CAMELOT and PREVENT analyzed the impact of blood pressure
variability (BPV, assessed as within-subject standard deviation of SBP from 12 weeks …

Background There is a paucity of evidence regarding the association between visit‐to‐visit
blood pressure variability and residual cardiovascular risk. We aimed to provide relevant …

We aim to determine if visit‐to‐visit blood pressure variability (BPV) adds prognostic value
for all‐cause mortality independently of the Framingham risk score (FRS) in the systolic …